Individual agents for treatment of ITP and the time to the first and peak responses if using the reported dose range
| Agent/treatment . | Reported dose range . | Time to initial response* . | Time to peak response* . |
|---|---|---|---|
| Prednisone4,44 | 1-4 mg/kg po daily × 1-4 wk | 4-14 d | 7-28 d |
| Dexamethasone48,49 | 40 mg po or iv daily × 4 d for 4-6 courses every 14-28 d | 2-14 d | 4-28 d |
| IVIg41,46,50 | 0.4-1 g/kg per dose iv (1-5 doses) | 1-3 d | 2-7 d |
| Anti-D42,47 | 75 μg/kg per dose iv | 1-3 d | 3-7 d |
| Rituximab10,40,51 | 375 mg/m2 per dose iv (4 weekly doses) | 7-56 d | 14-180 d |
| Splenectomy43 | Laparoscopic | 1-56 d | 7-56 d |
| Vincristine4 | up to 2 mg/dose iv (4-6 weekly doses) | 7-14 d | 7-42 d |
| Vinblastine4,45 | 0.1 mg/kg per dose iv (6 weekly doses) | 7-14 d | 7-42 d |
| Danazol4,52 | 400-800 mg po daily | 14-90 d | 28-180 d |
| Azathioprine52 | 2 mg/kg po daily | 30-90 d | 30-180 d |
| AMG5316,7,9 | 3-10 μg/kg weekly sc | 5-14 d | 14-60 d |
| Eltrombopag8 | 50-75 mg po daily | 7-28 d | 14-90 d |
| Agent/treatment . | Reported dose range . | Time to initial response* . | Time to peak response* . |
|---|---|---|---|
| Prednisone4,44 | 1-4 mg/kg po daily × 1-4 wk | 4-14 d | 7-28 d |
| Dexamethasone48,49 | 40 mg po or iv daily × 4 d for 4-6 courses every 14-28 d | 2-14 d | 4-28 d |
| IVIg41,46,50 | 0.4-1 g/kg per dose iv (1-5 doses) | 1-3 d | 2-7 d |
| Anti-D42,47 | 75 μg/kg per dose iv | 1-3 d | 3-7 d |
| Rituximab10,40,51 | 375 mg/m2 per dose iv (4 weekly doses) | 7-56 d | 14-180 d |
| Splenectomy43 | Laparoscopic | 1-56 d | 7-56 d |
| Vincristine4 | up to 2 mg/dose iv (4-6 weekly doses) | 7-14 d | 7-42 d |
| Vinblastine4,45 | 0.1 mg/kg per dose iv (6 weekly doses) | 7-14 d | 7-42 d |
| Danazol4,52 | 400-800 mg po daily | 14-90 d | 28-180 d |
| Azathioprine52 | 2 mg/kg po daily | 30-90 d | 30-180 d |
| AMG5316,7,9 | 3-10 μg/kg weekly sc | 5-14 d | 14-60 d |
| Eltrombopag8 | 50-75 mg po daily | 7-28 d | 14-90 d |
In the times to the initial and peak responses, the first number of days is the first time that a response could be reasonably expected and the second number of days is the time after which a response to this particular agent becomes less likely when administered at the dose and schedule listed in the table. Dosages, where not given on kilogram/body weight basis, are intended for adults.
po indicates per os administration; iv, intravenous infusion; and sc, subcutaneous infusion.